Posted by phidippus on June 11, 2014, at 17:55:03
In reply to Serzone or Trazodone for Depression?, posted by mogger on June 9, 2014, at 11:09:47
Nefazadone has been discontinued in some countries because it can cause liver damage/death due to liver damage.
Nefazodone acts primarily as a potent antagonist at the 5-HT2A receptors (Kd 26 nM). It also has moderate affinity for the α1-adrenergic receptor (Kd 48 nM) and 5-HT1A receptor (Kd 80 nM), and very low affinity for the α2-adrenergic receptor (Kd 640 nM) and D2 receptor (Kd 910 nM). Nefazodone has low affinity for the serotonin (200 nM), norepinephrine (360 nM), and dopamine (360 nM) transporters as well, and therefore acts as a weak serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI). It has negligible affinity for the H1 receptor (24,000 nM) or muscarinic acetylcholine receptors (11,000 nM), and accordingly lacks any antihistamine or anticholinergic side effects.~wikipedia
Post-synaptic 5-HT2A overdensity is involved in the pathogenesis of depression. Therefore, antagonizing this receptor should alleviate the effects of depression-this is the thinking behind Nefazadone.
Trazodone acts predominantly as a 5-HT2A receptor antagonist to mediate its therapeutic benefits against anxiety and depression. It is similar to Nefazadone in its action, however it is a much safer drug.
Curiously, Trazadone works a lot like Abilify.
Eric
poster:phidippus
thread:1066687
URL: http://www.dr-bob.org/babble/20140609/msgs/1066817.html